Showing 1 - 10 of 214
This paper discusses the relationship between medical innovations and ageing from a health economics perspective and surveys empirical evidence on medical R&D incentives, R&D costs of pharmaceuticals, and the cost-effectiveness of health innovations. Particular focus is on the endogeneity of...
Persistent link: https://www.econbiz.de/10012653346
Persistent link: https://www.econbiz.de/10003647197
The aim of this paper is to study the long-run effects of a longevity increase on individual decisions about education and retirement, taking macroeconomic repercussions through endogenous factor prices and the pension system into account. We build a model of a closed economy inhabited by...
Persistent link: https://www.econbiz.de/10010528342
their risks of both mortality and old-age dependence. We assume that the government cannot distinguish between bequests …
Persistent link: https://www.econbiz.de/10012304266
Analysis of population aging is typically framed in terms of chronological age. However, chronological age itself is not necessarily deeply informative about the aging process. This paper reviews literature and conducts empirical analyses aimed at investigating whether chronological age is a...
Persistent link: https://www.econbiz.de/10015098960
This paper studies the design of the optimal non linear taxation in an economy where longevity varies across agents, and depends on three factors: longevity genes, health investment and farsightedness. Provided earnings, farsightedness and genes are correlated, governmental intervention can be...
Persistent link: https://www.econbiz.de/10003831970
Persistent link: https://www.econbiz.de/10003598833
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10009571756
Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% G from 69.7 to 76.5 years G and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. While life expectancy has tended to increase, there...
Persistent link: https://www.econbiz.de/10011397757
Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at death), hospital utilization, and medical expenditure in Greece during the period 1995 - 2010. The estimates indicate that pharmaceutical innovation increased mean age at death...
Persistent link: https://www.econbiz.de/10010473542